PPD Recognized as a Best Place to Work in Asia
20 Luglio 2021 - 3:00PM
Business Wire
PPD, Inc. (Nasdaq: PPD) has been named one of the Best
Workplaces in Asia™ by Great Place to Work®, a global authority on
high-trust, high-performance workplace cultures.
PPD has more than 20 years of experience in the Asia-Pacific
region, including providing a broad range of clinical development
and laboratory services in greater China, such as a recently opened
multi-functional lab in Suzhou. The best-workplaces honor
recognizes PPD’s China-based business, known in the China drug
development and contracting research marketplace by the Mandarin
name Bai Shi Yi (百�益).
“We are honored to be recognized by Great Place to Work for the
second time in less than a year,” said Ding Ming, Ph.D., vice
president and general manager of PPD’s China operations. “This
award further reinforces our strong reputation as a preferred
employer in Greater China. We are committed to creating and
maintaining a healthy and open environment for all employees, and
we remain focused on recruiting highly qualified and engaging
candidates and developing them continuously to serve our customers
in China and around the world.”
Great Place to Work – which provides executive advisory and
culture consulting services to businesses, nonprofits and
government agencies – analyzes companies’ workplace programs and
surveys over half a million employees across Asia and the Middle
East about the key factors that create great workplaces. To be
considered for the regional honor, companies must be identified as
outstanding in their local country by appearing on one or more of
the country-specific Best Workplaces lists. In 2020, Great Place to
Work named PPD one of the Best Workplaces in Greater China™.
PPD continues to expand in the Asia-Pacific region to serve
local and global customers, with operations located across 14
countries. In May, PPD held a grand opening ceremony for its new
multipurpose laboratory in Suzhou, China, to support Western and
China-based pharmaceutical and biotech companies managing China
research studies. The 67,000-square-foot facility in the Suzhou New
District, Jiangsu Province, offers bioanalytical, biomarker and
vaccine laboratory services to support discovery research and
clinical trials across all phases of pharmaceutical development.
The new lab supplements the company’s Shanghai central lab,
established in 2015.
In Japan, PPD-SNBL – the joint venture of PPD and Shin Nippon
Biomedical Laboratories Ltd. (SNBL) – provides full-service
capabilities for customers and is known as an industry leader in
clinical trial delivery. PPD-SNBL has been recognized as a top-five
growth business and desirable employer, and commended for its
success with staff growth and retention, by Randstad Japan, a
subsidiary of Randstad N.V., a global leader in the human resources
services industry.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and
lifecycle management services. Our customers and partners include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With more than 28,000 professionals
worldwide, PPD has conducted clinical trials in more than 100
countries to help customers deliver life-changing therapies to
improve health. We apply innovative technologies, therapeutic
expertise and a firm commitment to quality to bend the cost and
time curve of drug development and optimize value. For more
information, visit www.ppd.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; the risks related to the proposed merger of
PPD by Thermo Fisher Scientific Inc.; and other factors disclosed
under the “Risk Factors” section in our periodic reports filed with
the Securities and Exchange Commission (SEC), including our latest
Annual Report on Form 10-K and Quarterly Report on form 10-Q, which
are available on our website at https://investors.ppd.com or the
SEC’s website at www.sec.gov. We assume no obligation and disclaim
any duty to revise or update any forward-looking statements, or
make any new forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210720005728/en/
Media: Nadine Maeser +1 919 456 4425 media@ppd.com Investors:
Tracy Krumme +1 910 558 4186 investors@ppd.com
Grafico Azioni Pharmaceutical Product Developme (NASDAQ:PPDI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Pharmaceutical Product Developme (NASDAQ:PPDI)
Storico
Da Set 2023 a Set 2024